Differential Side Effects Profile in Patients with MCRPC Treated with Abiraterone or Enzalutamide: a Meta-analysis of Randomized Controlled Trials

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Nov 16

PMID 29137449

Citations 40

Authors

Raphael B Moreira

Marcio Debiasi

Edoardo Francini

Pier V Nuzzo

Guillermo de Velasco

Fernando C Maluf

Andre P Fay

Joaquim Bellmunt

Toni K Choueiri

Fabio A Schutz

Affiliations

Soon will be listed here.

Abstract

Background: Abiraterone and enzalutamide are currently approved for mCRPC patients. Both drugs have distinct mechanisms of action and may have different toxicity profile. There are limited data comparing the side effects of abiraterone and enzalutamide. We performed a meta-analysis of randomized controlled trials (RCT) to better characterize the risk of adverse events associated with both drugs.

Methods: We performed a literature search on MEDLINE for studies reporting abiraterone and enzalutamide side effects from January 1966 to July 31, 2015. Abstracts presented at ASCO meetings from 2004 to 2015 were selected manually. Phase III RCT were included in analysis. We assessed the risk of adverse events reported in RCT by performing two meta-analyses: abiraterone-prednisone vs. placebo-prednisone (2,283 pts) and enzalutamide vs. placebo (2,914 pts). Summary of incidence, relative-risks (RR), and 95% confidence intervals (CI) were calculated using random-effects or fixed-effects models based on the heterogeneity of included studies.

Results: Overall, enzalutamide was not associated with all-grade (RR 1.06 - 95% CI 0.67-1.65) or grade ≥3 (RR 0.81 - 95% CI 0.28-2.33) cardiovascular events, but was associated with increased risk of all-grade fatigue (RR 1.29 - 95% CI 1.15-1.44). On the other hand, abiraterone was associated with increased risk of all-grade (RR 1.28 - 95% CI 1.06-1.55) and grade ≥3 (RR 1.76 - 95% CI 1.12-2.75) cardiovascular events, but was not associated with all-grade (RR 0.85 - 95% CI 0.58-1.23) or grade ≥3 (RR 1.07 - 95% CI 0.97-1.19) fatigue.

Conclusions: In this meta-analysis, abiraterone was associated with an increased risk of cardiovascular events, while enzalutamide was associated with an increased risk of fatigue.

Citing Articles

Luteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents.

Zhao J, Chen J, Sun G, Shen P, Zeng H Cancer Biol Med. 2024; 21(11).

PMID: 39718161 PMC: 11667785. DOI: 10.20892/j.issn.2095-3941.2024.0139.

Therapy resistance in prostate cancer: mechanism, signaling and reversal strategies.

Thakur N, Singh P, Bagri A, Srivastava S, Dwivedi V, Singh A Explor Target Antitumor Ther. 2024; 5(5):1110-1134.

PMID: 39351434 PMC: 11438573. DOI: 10.37349/etat.2024.00266.

Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).

Jensen J, Bobek O, Chan I, Miller B, Hillman D, Heller G Clin Cancer Res. 2024; 30(21):4910-4919.

PMID: 39287426 PMC: 11539927. DOI: 10.1158/1078-0432.CCR-24-0803.

Cardio-oncology in advanced prostate cancer.

Chen K, Wong T, Tan Y, Tay K, Tan W, Chan J Front Oncol. 2024; 14:1386597.

PMID: 38947889 PMC: 11211357. DOI: 10.3389/fonc.2024.1386597.

Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network.

Merseburger A, Bakshi G, Chen D, Chiong E, Jabbour M, Joung J World J Urol. 2024; 42(1):156.

PMID: 38483562 PMC: 10940372. DOI: 10.1007/s00345-024-04852-2.

References

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

Tsai H, DAmico A, Sadetsky N, Chen M, Carroll P . Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99(20):1516-24. DOI: 10.1093/jnci/djm168. View

Iacovelli R, Verri E, Cossu Rocca M, Aurilio G, Cullura D, de Cobelli O . The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. Eur J Cancer. 2015; 51(14):1970-7. DOI: 10.1016/j.ejca.2015.06.106. View

Rhodes V, Watson P, Hanson B . Patients' descriptions of the influence of tiredness and weakness on self-care abilities. Cancer Nurs. 1988; 11(3):186-94. View

Frank-Stromborg M, Wright P . Ambulatory cancer patients' perception of the physical and psychosocial changes in their lives since the diagnosis of cancer. Cancer Nurs. 1984; 7(2):117-30. View

Storey D, McLaren D, Atkinson M, Butcher I, Frew L, Smyth J . Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Ann Oncol. 2011; 23(6):1542-9. DOI: 10.1093/annonc/mdr447. View

Roviello G, Sigala S, Danesi R, Del Re M, Bonetta A, Cappelletti M . Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials. Crit Rev Oncol Hematol. 2016; 101:12-20. DOI: 10.1016/j.critrevonc.2016.02.013. View

Attard G, Reid A, Yap T, Raynaud F, Dowsett M, Settatree S . Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008; 26(28):4563-71. DOI: 10.1200/JCO.2007.15.9749. View

10.

Scher H, Fizazi K, Saad F, Taplin M, Sternberg C, Miller K . Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13):1187-97. DOI: 10.1056/NEJMoa1207506. View

11.

Keating N, OMalley A, Smith M . Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24(27):4448-56. DOI: 10.1200/JCO.2006.06.2497. View

12.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10):1006-12. DOI: 10.1016/j.jclinepi.2009.06.005. View

13.

Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R . Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based.... J Clin Oncol. 2015; 33(7):723-31. PMC: 4879718. DOI: 10.1200/JCO.2014.56.5119. View

14.

Neppl-Huber C, Zappa M, Coebergh J, Rapiti E, Rachtan J, Holleczek B . Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol. 2011; 23(5):1325-1334. DOI: 10.1093/annonc/mdr414. View

15.

Procopio G, Grassi P, Testa I, Verzoni E, Torri V, Salvioni R . Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. Am J Clin Oncol. 2013; 38(5):479-82. DOI: 10.1097/COC.0b013e3182a790ce. View

16.

Mukherji D, Omlin A, Pezaro C, Shamseddine A, de Bono J . Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. Cancer Metastasis Rev. 2014; 33(2-3):555-66. DOI: 10.1007/s10555-013-9473-1. View

17.

Beer T, Armstrong A, Rathkopf D, Loriot Y, Sternberg C, Higano C . Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371(5):424-33. PMC: 4418931. DOI: 10.1056/NEJMoa1405095. View

18.

de Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005. PMC: 3471149. DOI: 10.1056/NEJMoa1014618. View

19.

Stone P, Hardy J, Huddart R, AHern R, Richards M . Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer. 2000; 36(9):1134-41. DOI: 10.1016/s0959-8049(00)00084-8. View

20.

Nelson A, Gonzalez B, Jim H, Cessna J, Sutton S, Small B . Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer. 2016; 24(10):4159-66. PMC: 4995123. DOI: 10.1007/s00520-016-3241-z. View